Seeking Alpha EN

Instil Bio Non-GAAP EPS of -$0.97 beats by $2.81

Mar 27, 2026 &03042727202631; 11:04 UTC seekingalpha.com Trending 3/5

Read original on seekingalpha.com ↗

→

Neutral impact

Sentiment score: +5/100

Low impact Short-term (days)

WHAT THIS MEANS

Instil Bio reported a non-GAAP EPS of -$0.97, beating expectations by $2.81, but this is a biotech company with significant losses. The broader market is down 1.74% with VIX spiking 8.27%, indicating a risk-off environment that overshadows any single-stock positive earnings surprise.

AI CONFIDENCE

35% Low

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

⇅

INSTL

INSTLStock

High volatility expected

Positive earnings beat (+$2.81) is offset by macro headwinds (S&P -1.74%, VIX +8.27%). Biotech earnings beats often fade in risk-off markets. Insufficient conviction to call UP or DOWN.

↓

S&P 500

^GSPCIndex

Expected to decline

S&P 500 already down 1.74% with elevated VIX (29.71). Systemic risk-off environment dominates individual stock catalysts.

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Skip this trade. A single biotech earnings beat is noise in a 1.74% market decline with spiking fear. Wait for market stabilization or a clearer catalyst specific to INSTL's pipeline/cash runway. [MOVE:1.2%]

KEY SIGNALS

Earnings beat by $2.81 (positive)Still unprofitable (-$0.97 EPS)Macro risk-off environment (VIX +8.27%)S&P 500 down 1.74% — headwind for small-cap biotech

SECTORS INVOLVED

HealthcareBiotechnology

Analysis generated on Mar 27, 2026 at 11:20 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Instil Bio Non-GAAP EPS of -$0.97 beats by $2.81

RELATED INTELLIGENCE